167 related articles for article (PubMed ID: 34312220)
1. Chemoradiation versus radiation alone in stage IIIB cervical cancer patients with or without human immunodeficiency virus.
Grover S; Ning MS; Bale M; Lichter KE; Shah S; Bvochora-Nsingo M; Chiyapo S; Balang D; McGinnis GJ; Ralefala T; Moloi T; Luckett R; Ramogola-Masire D; Robertson ES; Zetola NM
Int J Gynecol Cancer; 2021 Sep; 31(9):1220-1227. PubMed ID: 34312220
[TBL] [Abstract][Full Text] [Related]
2. Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting.
Grover S; Bvochora-Nsingo M; Yeager A; Chiyapo S; Bhatia R; MacDuffie E; Puri P; Balang D; Ratcliffe S; Narasimhamurthy M; Gwangwava E; Tsietso S; Kayembe MKA; Ramogola-Masire D; Dryden-Peterson S; Mahantshetty U; Viswanathan AN; Zetola NM; Lin LL
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):201-210. PubMed ID: 29619965
[TBL] [Abstract][Full Text] [Related]
3. Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa.
Simonds HM; Wright JD; du Toit N; Neugut AI; Jacobson JS
Cancer; 2012 Jun; 118(11):2971-9. PubMed ID: 22072021
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. HIV Status and Acute Hematologic Toxicity Among Patients With Cervix Cancer Undergoing Radical Chemoradiation.
Simonds HM; Neugut AI; Jacobson JS
Int J Gynecol Cancer; 2015 Jun; 25(5):884-90. PubMed ID: 25853380
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
[TBL] [Abstract][Full Text] [Related]
7. Prospective quality of life study of South African women undergoing treatment for advanced-stage cervical cancer.
du Toit GC; Kidd M
Clin Ther; 2015 Oct; 37(10):2324-31. PubMed ID: 26385584
[TBL] [Abstract][Full Text] [Related]
8. Prediction scoring system based on clinicohematologic parameters for cervical cancer patients undergoing chemoradiation.
Kim YJ; Kim YS; Shin JW; Osong B; Lee SH
Int J Gynecol Cancer; 2020 Nov; 30(11):1689-1696. PubMed ID: 32546642
[TBL] [Abstract][Full Text] [Related]
9. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
10. Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
Meghani K; Puri P; Bazzett-Matabele L; Vuylsteke P; Luckett R; Monare B; Chiyapo S; Ketlametswe R; Ralefala TB; Bvochora-Nsingo M; Zetola N; Ramogola-Masire D; Grover S
Cancer; 2024 Mar; ():. PubMed ID: 38529676
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation.
Scott AA; Yarney J; Vanderpuye V; Akoto Aidoo C; Agyeman M; Boateng SN; Sasu E; Anarfi K; Obeng-Mensah T
Int J Gynecol Cancer; 2021 May; 31(5):670-678. PubMed ID: 33558421
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
13. A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients.
Buckstein M; Arens Y; Wisnivesky J; Gaisa M; Goldstone S; Sigel K
Dis Colon Rectum; 2018 Jul; 61(7):787-794. PubMed ID: 29771796
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.
Montes de Oca MK; Albright BB; Secord AA; Havrilesky LJ; Moss HA
Int J Gynecol Cancer; 2021 Dec; 31(12):1549-1556. PubMed ID: 34725205
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
DeBoer RJ; Umutoni V; Bazzett-Matabele L; Katznelson E; Nguyen C; Umwizerwa A; Bigirimana JB; Paciorek A; Nsabimana N; Ruhangaza D; Ntasumbumuyange D; Shulman LN; Triedman SA; Shyirambere C
Gynecol Oncol; 2022 Feb; 164(2):370-378. PubMed ID: 34916066
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.
Einstein MH; Ndlovu N; Lee J; Stier EA; Kotzen J; Garg M; Whitney K; Lensing SY; Tunmer M; Kadzatsa W; Palefsky J; Krown SE
Gynecol Oncol; 2019 Apr; 153(1):20-25. PubMed ID: 30773222
[TBL] [Abstract][Full Text] [Related]
18. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.
Marnitz S; Tsunoda AT; Martus P; Vieira M; Affonso Junior RJ; Nunes J; Budach V; Hertel H; Mustea A; Sehouli J; Scharf JP; Ulrich U; Ebert A; Piwonski I; Kohler C
Int J Gynecol Cancer; 2020 Dec; 30(12):1855-1861. PubMed ID: 33293284
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
20. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation.
Raut A; Chopra S; Mittal P; Patil G; Mahantshetty U; Gurram L; Swamidas J; Ghosh J; Gulia S; Popat P; Deodhar K; Maheshwari A; Gupta S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1248-1256. PubMed ID: 32681859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
